Search
OmniAb Inc
OABIAdd to Watchlist
2.420USD
+0.030+1.26%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
349.23MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of OmniAb Inc is 8.57, ranking 100 out of 387 in the Biotechnology & Medical Research industry. The average price target is 8.00, with a high of 11.00 and a low of 3.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
7.333
Target Price
+206.83%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
OmniAb Inc
OABI
7
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is OmniAb Inc's expected revenue for the next quarter?
OmniAb Inc's expected revenue is 4.69M.
What is OmniAb Inc's price target?
Analysts forecast that OmniAb Inc's price target is USD 8.00, with the highest forecast at USD 11.00 and the lowest forecast at USD 3.00.
How have OmniAb IncOABI's recent earnings per share performed?
The market expectation was USD -0.06, while OmniAb IncOABI's earnings per share (EPS) for the previous quarter was USD -0.11. EPS for the next quarter is expected at USD -0.12.
What is the analyst rating for OmniAb Inc?
Based on the ratings of OmniAb Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.